Crossvault Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | $9.69M | Sell |
184,742
-6,100
| -3% | -$311K | 3.81% | 6 |
|
|
2022
Q1 | $9.88M | Sell |
190,842
-1,004
| -0.5% | -$52.1K | 3.18% | 9 |
|
|
2021
Q4 | $11.3M | Sell |
191,846
-2,100
| -1% | -$104K | 3.4% | 8 |
|
|
2021
Q3 | $8.34M | Buy |
193,946
+25,080
| +15% | +$1.11M | 2.63% | 17 |
|
|
2021
Q2 | $7.23M | Buy |
168,866
+10,605
| +7% | +$412K | 2.2% | 19 |
|
|
2021
Q1 | $5.73M | Buy |
158,261
+605
| +0.4% | +$21.5K | 2.04% | 22 |
|
|
2020
Q4 | $5.8M | Buy |
157,656
+6,586
| +4% | +$242K | 2.16% | 21 |
|
|
2020
Q3 | $5.26M | Buy |
151,070
+22,151
| +17% | +$777K | 2.28% | 18 |
|
|
2020
Q2 | $4M | Buy |
128,919
+70,007
| +119% | +$2.38M | 1.85% | 22 |
|
|
2020
Q1 | $1.82M | Sell |
58,912
-422
| -0.7% | -$14.4K | 1.02% | 30 |
|
|
2019
Q4 | $2.21M | Sell |
59,334
-2,846
| -5% | -$101K | 0.97% | 29 |
|
|
2019
Q3 | $2.12M | Hold |
62,180
| – | – | 1.01% | 29 |
|
|
2019
Q2 | $2.56M | Buy |
62,180
+317
| +0.5% | +$12.6K | 1.25% | 27 |
|
|
2019
Q1 | $2.49M | Sell |
61,863
-211
| -0.3% | -$8.45K | 1.29% | 26 |
|
|
2018
Q4 | $2.57M | Buy |
62,074
+20,972
| +51% | +$871K | 1.46% | 23 |
|
|
2018
Q3 | $1.72M | Hold |
41,102
| – | – | 0.89% | 30 |
|
|
2018
Q2 | $1.42M | Buy |
41,102
+6,851
| +20% | +$234K | 0.75% | 31 |
|
|
2018
Q1 | $1.15M | Sell |
34,251
-211
| -0.6% | -$7.25K | 0.66% | 33 |
|
|
2017
Q4 | $1.18M | Hold |
34,462
| – | – | 0.62% | 37 |
|
|
2017
Q3 | $1.17M | Hold |
34,462
| – | – | 0.67% | 36 |
|
|
2017
Q2 | $1.1M | Hold |
34,462
| – | – | 0.66% | 36 |
|
|
2017
Q1 | $1.12M | Sell |
34,462
-107,237
| -76% | -$3.38M | 0.7% | 38 |
|
|
2016
Q4 | $4.37M | Sell |
141,699
-4,790
| -3% | -$146K | 2.95% | 13 |
|
|
2016
Q3 | $4.71M | Buy |
146,489
+1,346
| +0.9% | +$45K | 3.28% | 9 |
|
|
2016
Q2 | $4.85M | Sell |
145,143
-1,083
| -0.7% | -$34.6K | 3.43% | 9 |
|
|
2016
Q1 | $4.11M | Sell |
146,226
-1,844
| -1% | -$52.7K | 3.03% | 15 |
|
|
2015
Q4 | $4.54M | Buy |
148,070
+2,337
| +2% | +$73.5K | 3.22% | 10 |
|
|
2015
Q3 | $4.34M | Buy |
145,733
+6,467
| +5% | +$207K | 3.39% | 9 |
|
|
2015
Q2 | $4.43M | Sell |
139,266
-1,186
| -0.8% | -$38.7K | 3.54% | 8 |
|
|
2015
Q1 | $4.64M | Buy |
140,452
+5,950
| +4% | +$189K | 3.71% | 5 |
|
|
2014
Q4 | $3.98M | Buy |
134,502
+6,205
| +5% | +$178K | 3.48% | 6 |
|
|
2014
Q3 | $3.6M | Sell |
128,297
-1,281
| -1% | -$36K | 3.4% | 12 |
|
|
2014
Q2 | $3.65M | Buy |
129,578
+7,415
| +6% | +$211K | 3.4% | 10 |
|
|
2014
Q1 | $3.72M | Buy |
122,163
+4,322
| +4% | +$129K | 3.61% | 7 |
|
|
2013
Q4 | $3.42M | Buy |
+117,841
| New | +$3.43M | 3.31% | 9 |
|
Other funds holding PFE
Crossvault Capital Management's PFE Position: Q2 2022 in Review
Crossvault Capital Management reduced its Pfizer (PFE) stake by 3.2% in Q2 2022, selling an estimated $311K and leaving 184,742 shares worth $9.69M. The position accounts for 3.81% of the portfolio, ranked #6.
Crossvault Capital Management first reported a position in PFE in Q4 2013 and has held it in 35 quarters since. The position peaked at $11.3M in Q4 2021. 3,157 funds tracked by Wall St. Rank hold PFE as of Q2 2022.
- Crossvault Capital Management held 184,742 shares of Pfizer worth $9.69M as of Q2 2022.
- Crossvault Capital Management sold 6,100 Pfizer shares in Q2 2022, an estimated $311K.
- Pfizer made up 3.81% of Crossvault Capital Management's portfolio in Q2 2022, its #6 holding.
- Crossvault Capital Management first reported a position in Pfizer in Q4 2013 and has held it in 35 quarters since.
- Crossvault Capital Management's Pfizer position peaked at $11.3M in Q4 2021.
- 3,157 funds tracked by Wall St. Rank held Pfizer as of Q2 2022.
Based on Crossvault Capital Management's 13F filing for Q2 2022, filed 8 Aug 2022.